RULES TO REDUCE FROM 63 10/25/2013 DISCLOSURES EVIDENCE BASED MEDICINE
|
|
- Franklin May
- 5 years ago
- Views:
Transcription
1 DISCLOSURES No Conflicts of Interest to Disclose WHICH RA DISEASE ACTIVITY MEASURES TO USE IN PRACTICE Mark Robbins, M.D. MPH Co-Chair Quality Measures ACR Atrius Health - Boston My primary involvement with the RA Disease Activity Workgroup was in major revisions of the original draft. Acknowledge that Kaleb Michaud graciously gave me license to use slides outlining the stepwise process and decisions along the way. EVIDENCE BASED MEDICINE Anderson et al. Rheumatoid Arthritis Disease Activity Measures: American College of Rheumatology Recommendations for Use in Clinical Practice. Arthritis Care and Research Anderson et al. Measures of Rheumatoid Arthritis Disease Activity... Arthritis Care and Research Maska et al. Measures of Functional Status and Quality of Life in Rheumatoid Arthritis. Arthritis Care and Research ACR DISEASE ACTIVITY MEASURES PROJECT WORKING GROUP Mission: Comprehensively evaluate the validity, feasibility, and acceptability of available RA disease activity measures (DAM). Derive recommendations for their use in clinical practice Translation: Let s figure out what you should measure for RA in your clinic! Let s allow enough flexibility in measure selection that different practice environments (small single specialty vs. large multispecialty and academic medical centers) with different priorities and levels of support can pick the best measure for their needs. SYSTEMATIC REVIEW FOUND 63 RA DAMS! Multidimensional Health Assessment Rheumatoid Arthritis Impact of Disease ACR Core Set American College of Rheumatology Core Set RAID Questionnaire Score American College of Rheumatology Hybrid ACR Hybrid mhaq Modified Health Assessment Questionnaire RAPID 2 Response Measure with 2 measures ACR-N American College of Rheumatology - N MJS Mechanical Joint Score RAPID 3 with 3 measures AIMS Arthritis Impact Measurement Scale MSS Modified Sharp Score RAPID4MDJC with 4 measures and MD Joint Count Arthritis Impact Measurement Scale Revised AIMS2 MOI-RA Mean Overall Index for Rheumatoid Arthritis RAPID4PTJC Version with 4 measures and Patient Joint Count CASI Chronic Arthritis Systemic Index Mallya and Mace Mallya and Mace Index RAPID 5 with 5 measures CDAI Chronic Disease Activity Index NHP Nottingham Health Profile RAQoL Rheumatoid Arthritis Quality of Life Cochin Rheumatoid Arthritis Hand Functional Cochin NOAR Norfolk Arthritis Register Damaged RASS Rheumatoid Arthritis Severity Scale Joint Count Disability Scale DAS Disease Activity Score OSRA Overall Status in Rheumatoid Arthritis Riel Riel Index DAS 28 Disease Activity Score with 28 Joint Counts PAS Patient Activity Scale ROAD Index Recent-Onset Arthritis Disability Index Score for Assessment and Quantification of EULAR European League Against Rheumatism Core PASII Patient Activity Scale II SACRAH Set Chronic Rheumatic Affections of the Hands EuroQoL European Quality of Life Measure Paulus Paulus Criteria Scott Scott Index GAS Global Arthritis Score PDAS1 Patient-Based Disease SDAI Simplified Disease Activity Index Activity Score with ESR HAQ Health Assessment Questionnaire PDAS2 Patient-Based Disease Activity Score without ESR SF-36 Short Form 36-Item Health Survey Short Form 36-Item Arthritis Specific HAQ-II Health Assessment Questionnaire Pooled Pooled Index SF-36 ASHI II Health Index Provider Global Assessment of Disease Activity HRAS38 Handy RA Activity Score with 38 Joints PrGlobal Sharp Score Sharp Score Patient Global Assessment of Disease Activity IDA Index of Disease Activity PtGlobal SIP Sickness Impact Profile Lansbury Lansbury Index RADAI Rheumatoid Arthritis Disease Activity Index Stoke Index Stoke Index Larsen Larsen Score RADAI 5 Rheumatoid Arthritis Disease Activity Index 5 TSC Therapeutic Score Card Mean Percentage of Improvement in the American Rapid Assessment of Disease Activity in World Health Organization and macr RADAR WHO/ILAR International League Against Rheumatism College of Rheumatology 7 Core Set Measures Rheumatology Response Criteria Real Time Assessment of Disease Activity in World Health Organization Disability MAL Measurement of Activity Limitation RADARA WHODASII Rheumatoid Arthritis Assessment Schedule II RULES TO REDUCE FROM 63 Measured radiographic changes only: 3 Did not report a continuous value: 5 Pertained only to joint damage or disability: 3 Had insufficient information: 5 RADAMs remaining: 47 1
2 RULES TO REDUCE FROM 47 Not recommend by expert panel: 14 Measured quality of life: 10 Required calculation of change score: 2 Antiquated measure: 1 Pertains only to single body region: 1 RADAMs remaining: 19 RULES TO REDUCE FROM 19 Lacked Remission Criteria: 5 Submitted to ACR membership (N=335) Ranked low: 5 Low use reported: 1 Lacked well-defined disease activity categories: 2 RADAMs remaining: 6! FROM 63 TO 6 ACR Core Set American College of Rheumatology Core Set Multidimensional Health Assessment Questionnaire RAID American College of Rheumatology Hybrid ACR Hybrid mhaq Modified Health Assessment Questionnaire RAPID 2 Response Measure ACR-N American College of Rheumatology - N MJS Mechanical Joint Score RAPID 3 Rheumatoid Arthritis Impact of Disease Score with 2 measures with 3 measures FINAL LIST OF 6 RA DAMS AIMS Arthritis Impact Measurement Scale MSS Modified Sharp Score RAPID4MDJC with 4 measures and MD Joint Count Arthritis Impact Measurement Scale Revised AIMS2 MOI-RA Mean Overall Index for Rheumatoid Arthritis RAPID4PTJC Version with 4 measures and Patient Joint Count CASI Chronic Arthritis Systemic Index Mallya and Mace Mallya and Mace Index RAPID 5 with 5 measures CDAI Chronic Disease Activity Index NHP Nottingham Health Profile RAQoL Rheumatoid Arthritis Quality of Life Cochin Rheumatoid Arthritis Hand Functional Cochin NOAR Norfolk Arthritis Register Damaged RASS Rheumatoid Arthritis Severity Scale Joint Count Disability Scale DAS Disease Activity Score OSRA Overall Status in Rheumatoid Arthritis Riel Riel Index DAS 28 Disease Activity Score with 28 Joint Counts PAS Patient Activity Scale ROAD Index Recent-Onset Arthritis Disability Index Score for Assessment and Quantification of EULAR European League Against Rheumatism Core PASII Patient Activity Scale II SACRAH Set Chronic Rheumatic Affections of the Hands EuroQoL European Quality of Life Measure Paulus Paulus Criteria Scott Scott Index GAS Global Arthritis Score PDAS1 Patient-Based Disease SDAI Simplified Disease Activity Index Activity Score with ESR HAQ Health Assessment Questionnaire PDAS2 Patient-Based Disease Activity Score without ESR SF-36 Short Form 36-Item Health Survey Short Form 36-Item Arthritis Specific HAQ-II Health Assessment Questionnaire Pooled Pooled Index SF-36 ASHI II Health Index Provider Global Assessment of Disease Activity HRAS38 Handy RA Activity Score with 38 Joints PrGlobal Sharp Score Sharp Score Patient Global Assessment of Disease Activity IDA Index of Disease Activity PtGlobal SIP Sickness Impact Profile Lansbury Lansbury Index RADAI Rheumatoid Arthritis Disease Activity Index Stoke Index Stoke Index DAS-28 Disease Activity Score 28 joints CDAI Chronic Disease Activity Index SDAI Simplified Disease Activity Index RAPID-3 Routine Assessment of Patient Index Data w 3 measures PAS Patient Activity Scale PAS-II Patient Activity Scale II Larsen Larsen Score RADAI 5 Rheumatoid Arthritis Disease Activity Index 5 TSC Therapeutic Score Card Mean Percentage of Improvement in the American macr RADAR College of Rheumatology 7 Core Set Measures MAL Measurement of Activity Limitation RADARA Rapid Assessment of Disease Activity in Rheumatology Real Time Assessment of Disease Activity in Rheumatoid Arthritis WHO/ILAR WHODASII World Health Organization and International League Against Rheumatism Response Criteria World Health Organization Disability Assessment Schedule II RA DAM 3 DATA SOURCES RA DAM COMPONENTS BY SOURCE Patient Lab Patient Lab Pain VAS Global Function (HAQ) ESR CRP Provider Provider Global Swollen Joint Count Tender Joint Count 2
3 RA DAM FINAL 6 DAMS Measure Scale RA DAM CUTOFFS Level of Disease Activity Patient PAS PAS-II RAPID-3 CDAI DAS-28 SDAI Lab Remission Low Medium High PAS 0-10 <0.25 <3.70 < PAS-II 0-10 <0.25 <3.70 < RAPID < CDAI Provider SDAI DAS <2.6 < DIFFERENCES IN PATIENT- REPORTED MEASURES All three use pain and patient global Difference only in functional assessment PAS uses HAQ RAPID-3 uses PAS-II uses HAQ-II THE HAQ FAMILY A B R I E F V I S I T W I T H WHAT IS THE HAQ? Stanford (Health Assessment Questionnaire)Disability Index Jim Fries 20 Likert-questions 21 Aid/devices questions Designed to be a generic measure of function 3
4 WHICH TO USE FOR YOUR CLINIC? Depends on your clinic Laboratory measure - greatest limitation Provider measures? HAQ GOLD STANDARD WIDE RANGE OF FUNCTION THEN CAME MHAQ MHAQ Modified HAQ, Ted Pincus, 1983 Much shorter 8 questions: 1 from each of 8 dimensions of the HAQ 4
5 MHAQ THEN CAME MD-HAQ Multidimensional HAQ Ted Pincus, 1999 Added 2 new questions to the MHAQ Participate in Sports Walk 2 miles on flat ground HAQ-II Fred Wolfe, Kaleb Michaud (& Ted Pincus) questions, 5 from HAQ, 5 new Used IRT/Rasch analysis to develop Most efficient way of determining function score (using HAQ as standard), with least number of questions Better at distinguishing differences in function 5
6 HAQ-II THE RA HAQ FAMILY DIFFERENCES BETWEEN PATIENT-REPORTED RA DAMS All three use pain and patient global assessment Differences due to functional assessment PAS uses HAQ RAPID3 uses PAS-II uses HAQ-II PAS, PAS-II, RAPID-3 HAQ FAMILY SUMMARY PROVIDER RA DAMS While all HAQs are valid measures of function, the HAQ & HAQ-II are better at distinguishing differences in function (responsive) than MHAQ & If starting from scratch, PAS-II may be best, since it incorporates the HAQ-II - so faster than full HAQ and potentially better at distinguishing changes in function. DAS-28 Hard to calculate DAS-28 = 0.56xSqrt(28TJC) xSqrt(28SJC) xln(ESR) xPatGlobal Remission may still have several swollen joints, specifically excludes small joints of the feet Lab components (esr, crp) may not be resulted before or at the enconuter when clinical decisions need to be made. CDAI (& SDAI) 28TJC + 28SJC + PrGlobal + PatGlobal (+CRP) SDAI 3.3 is ACR/EULAR remission criteria 6
7 CONCLUSIONS There is no ideal measure of disease activity Measures excluded in [this] review could later be found to possess... superior psychometric properties to the 6 recommended. Knowing the data source (patient, provider, lab), the subtleties of individual data elements, and overlaps between the measures is important to fully understand what you are actually measuring in a composite scoring system Computerized branching algorithmic measures (PROMIS) have the potential to break new ground in the field of composite disease activity measurement 7
Supplemental Table 1. Key Inclusion Criteria Inclusion Criterion OPTIMA PREMIER 18 years old with RA (per 1987 revised American College of General
Supplemental Table 1. Key Inclusion Criteria Inclusion Criterion OPTIMA PREMIER 18 years old with RA (per 1987 revised American College of General Rheumatology classification criteria) 34 ; erythrocyte
More informationNew Evidence reports on presentations given at EULAR Tocilizumab for the Treatment of Rheumatoid Arthritis
New Evidence reports on presentations given at EULAR 2012 Tocilizumab for the Treatment of Rheumatoid Arthritis Report on EULAR 2012 presentations Tocilizumab monotherapy is superior to adalimumab monotherapy
More informationCorrespondence should be addressed to Martin J. Bergman;
Autoimmune Diseases Volume 2013, Article ID 367190, 7 pages http://dx.doi.org/10.1155/2013/367190 Research Article Composite Indices Using 3 or 4 Components of the Core Data Set Have Similar Predictive
More informationNew Evidence reports on presentations given at EULAR Tocilizumab for the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis
New Evidence reports on presentations given at EULAR 2011 Tocilizumab for the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis Report on EULAR 2011 presentations Benefit of continuing
More informationBest Parameters for Assessment of Anti-Rheumatoid. (Economical, Clinical and Humanistic Outcome)
Int. J. Bioinformatics and Biological Sci.: v.2 n.1&2, p. 85-94. March and June 2014 Best Parameters for Assessment of Anti-Rheumatoid Arthritic Drugs is ECHO MODEL (Economical, Clinical and Humanistic
More informationOutcomes Research in Rheumatoid arthritis Ushering in a new era
Review Article Outcomes Research in Rheumatoid arthritis Ushering in a new era *Suseem 1, Emily James 1,2, Mathew George 2 * Assistant Professor Senior, School of Advanced Sciences (SAS), Vellore Institute
More informationBest Practices in Managing Patients with Rheumatoid Arthritis. Cornerstone Health Care, P.A. Collecting and Measuring RA Data
Best Practices in Managing Patients with Rheumatoid Arthritis, P.A. Collecting and Measuring RA Data Organizational Profile opened in 1995 in High Point, North Carolina, as a multidisciplinary group of
More informationEfficacy and Safety of Tocilizumab in the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis
New Evidence reports on presentations given at EULAR 2010 Efficacy and Safety of Tocilizumab in the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis Report on EULAR 2010 presentations
More informationIntegrating Quality Measures for RA into Your Practice: Optimizing Patient Care Using Your Own Data
Integrating Quality Measures for RA into Your Practice: Optimizing Patient Care Using Your Own Data Robin K. Dore, MD Clinical Professor of Medicine David Geffen School of Medicine at UCLA Los Angeles,
More informationConcept of measurement: RA defining decrements in physical functioning
Concept of measurement: RA defining decrements in physical functioning Jasvinder Singh, MD, MPH Associate Professor of Medicine and Epidemiology, University of Alabama at Birmingham Staff Physician, Birmingham
More informationAssessing Remission in Rheumatoid Arthritis on the Basis of Patient Reported Outcomes
136 Bulletin of the Hospital for Joint Diseases 2014;72(2):136-41 Assessing Remission in Rheumatoid Arthritis on the Basis of Patient Reported Outcomes Advantages of Using RAPID3/MDHAQ in Routine Care
More informationTHEODORE PINCUS, CHRISTOPHER J. SWEARINGEN, MARTIN BERGMAN, and YUSUF YAZICI
RAPID3 (Routine Assessment of Patient Index Data 3), a Rheumatoid Arthritis Index Without Formal Joint Counts for Routine Care: Proposed Severity Categories Compared to Disease Activity Score and Clinical
More informationElectronic MDHAQ / T. Pincus
Electronic multidimensional health assessment questionnaire (emdhaq): past, present and future of a proposed single data management system for clinical care, research, quality improvement, and monitoring
More informationNew Evidence reports on presentations given at EULAR Safety and Efficacy of Tocilizumab as Monotherapy and in Combination with Methotrexate
New Evidence reports on presentations given at EULAR 2009 Safety and Efficacy of Tocilizumab as Monotherapy and in Combination with Methotrexate Report on EULAR 2009 presentations Tocilizumab inhibits
More information2.0 Synopsis. Adalimumab (HUMIRA ) W Clinical Study Report R&D/15/0629. Individual Study Table Referring to Part of Dossier: Volume:
2.0 Synopsis AbbVie Inc. Name of Study Drug: Adalimumab / HUMIRA Name of Active Ingredient: Adalimumab Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only)
More informationT. Pincus 1, B. Richardson 2, V. Strand 3, M.J. Bergman 4
Relative efficiencies of the 7 rheumatoid arthritis Core Data Set measures to distinguish active from control treatments in 9 comparisons from clinical trials of 5 agents T. Pincus 1, B. Richardson 2,
More informationACR ARHP. The Need for Patient Assessment Tools for Early Detection of Flares. Individualizing Patient Care in Rheumatoid Arthritis:
R E P O R T F R O M ACR ARHP 2008 Annual Scientific Meeting Individualizing Patient Care in Rheumatoid Arthritis: The Need for Patient Assessment Tools for Early Detection of Flares CAnadian Vision for
More informationThe new ACR/EULAR remission criteria: rationale for developing new criteria for remission
RHEUMATOLOGY Rheumatology 2012;51:vi16 vi20 doi:10.1093/rheumatology/kes281 The new ACR/EULAR remission criteria: rationale for developing new criteria for remission Vivian P. Bykerk 1,2 and Elena M. Massarotti
More informationTreat - to - Target Pathway Commissioning Chronic and Complex Care MIDLANDS RHEUMATOLOGY & MUSCULOSKELETAL (MSK) COMMISSIONING NETWORK
Treat - to - Target Pathway Commissioning Chronic and Complex Care MIDLANDS RHEUMATOLOGY & MUSCULOSKELETAL (MSK) COMMISSIONING NETWORK Dr Bruce Kirkham Consultant Rheumatologist Guy s & St Thomas NHS Foundation
More informationCitation for final published version:
This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: http://orca.cf.ac.uk/97756/ This is the author s version of a work that was submitted to / accepted
More informationT. Uhlig, E. A. Haavardsholm and T. K. Kvien
Rheumatology 2006;45:454 458 Advance Access publication 15 November 2005 Comparison of the Health Assessment Questionnaire (HAQ) and the modified HAQ (MHAQ) in patients with rheumatoid arthritis T. Uhlig,
More informationM. Schoels 1, F. Alasti 2, J. S. Smolen 1,2 and D. Aletaha 2*
Schoels et al. Arthritis Research & Therapy (2017) 19:155 DOI 10.1186/s13075-017-1346-5 RESEARCH ARTICLE Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28)
More informationIndividual Patient Characteristics Are There Differences in Responsiveness: Or How to Characterize Patients for Pivotal Trials
Individual Patient Characteristics Are There Differences in Responsiveness: Or How to Characterize Patients for Pivotal Trials Lee S. Simon, MD SDG LLC Cambridge, MA Consulting Affinergy Astrazeneca Abraxxis
More informationABSTRACT. Keywords: Africa; Efficacy; Etanercept; Maintenance therapy; Middle East; Rheumatoid arthritis ORIGINAL RESEARCH
Rheumatol Ther (2018) 5:149 158 https://doi.org/10.1007/s40744-018-0094-6 ORIGINAL RESEARCH Maintenance of Remission with Etanercept DMARD Combination Therapy Compared with DMARDs Alone in African and
More informationMeasuring Patient Outcomes:
Measuring Patient Outcomes: Interplay of science, policy and marketing Chapel Hill, November 22, 22 Dr. Claire Bombardier Professor of Medicine, University of Toronto Senior Scientist, Institute for Work
More informationClinical and Experimental Rheumatology 2010; 28:
Psychometric properties of an index of three patient-reported outcome (PRO) measures, termed the CLinical ARthritis Activity (PRO-CLARA) in patients with rheumatoid arthritis. The NEW INDICES study F.
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies Comparative Effectiveness Studies of Biologics Learning Objectives Understand the motivation for comparative effectiveness research
More informationQuantitative documentation of benefit/risk of new therapies for rheumatoid arthritis: Patient questionnaires as an optimal measure in standard care
Quantitative documentation of benefit/risk of new therapies for rheumatoid arthritis: Patient questionnaires as an optimal measure in standard care T. Pincus 1, T. Sokka 1,2, A. Kavanaugh 3 1 Division
More informationGenetic variation in FOXO3 is associated with reductions in inflammation and disease activity in inflammatory polyarthritis
Genetic variation in FOXO3 is associated with reductions in inflammation and disease activity in inflammatory polyarthritis Sebastien Viatte 1, James C. Lee 3,4, Bo Fu 1,5, Marion Espéli 6, Mark Lunt 7,
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationRheumatoid arthritis (RA) cannot be assessed in individual
211 RAPID3 An Index of Physical Function, Pain, and Global Status as Vital Signs to Improve Care for People with Chronic Rheumatic Diseases Theodore Pincus, M.D., Martin J. Bergman, M.D., F.A.C.R., F.A.C.P.,
More informationRheumatoid arthritis 2010: Treatment and monitoring
October 12, 2010 By Yusuf Yazici, MD [1] The significant changes in the way rheumatoid arthritis has been managed include earlier, more aggressive treatment with combination therapy. Significant changes
More informationEffect of Formal Education Level on Measurement of Rheumatoid Arthritis Disease Activity
Journal of Rheumatic Diseases Vol. 22, No. 4, August, 2015 http://dx.doi.org/10.4078/jrd.2015.22.4.231 Original Article Effect of Formal Education Level on Measurement of Rheumatoid Arthritis Disease Activity
More informationGSK 165: anti-gm-csf antibody
GSK 165: anti-gm-csf antibody A novel mechanism with potentially differentiated impact on pain in the treatment of Rheumatoid Arthritis 23 October 2018 Cautionary statement regarding forward-looking statements
More informationNew Evidence reports on presentations given at ACR Improving Radiographic, Clinical, and Patient-Reported Outcomes with Rituximab
New Evidence reports on presentations given at ACR 2009 Improving Radiographic, Clinical, and Patient-Reported Outcomes with Rituximab From ACR 2009: Rituximab Rituximab in combination with methotrexate
More informationThe provisional ACR/EULAR definition of remission in RA: a comment on the patient global assessment criterion
RHEUMATOLOGY Rheumatology 2012;51:1076 1080 doi:10.1093/rheumatology/ker425 Advance Access publication 1 February 2012 CLINICAL SCIENCE Concise report The provisional ACR/EULAR definition of remission
More informationJames R. O Dell, M.D. University of Nebraska Medical Center
Not everyone in the world needs a biologic: Lessons from TEAR and RACAT James R. O Dell, M.D. University of Nebraska Medical Center Disclosure Declaration James O Dell, MD Advisory Board for Crescendo,
More informationIn patients with inflammatory conditions, including rheumatoid
ORIGINAL ARTICLE Comparison of Physician and Patient Global Assessments Over Time in Patients With Rheumatoid Arthritis A Retrospective Analysis From the RADIUS Cohort Joseph A. Markenson, MD, FACP,* Andrew
More informationNICE DECISION SUPPORT UNIT
SEQUENTIAL TNF-α INHIBITORS AND NON BIOLOGIC DMARDS ANALYSIS OF THE NATIONAL DATABANK FOR RHEUMATIC DISEASES. NICE DECISION SUPPORT UNIT Allan Wailoo School of Health and Related Research, University of
More informationReceived: 27 May 2003 Revisions requested: 26 Jun 2003 Revisions received: 14 Aug 2003 Accepted: 19 Aug 2003 Published: 1 Oct 2003
Research article Etanercept versus etanercept plus methotrexate: a registrybased study suggesting that the combination is clinically more efficacious Ronald F van Vollenhoven 1, Sofia Ernestam 2, Anders
More information1.0 Abstract. Title. Keywords. Rationale and Background
1.0 Abstract Title A Prospective, Multi-Center Study in Rheumatoid Arthritis Patients on Adalimumab to Evaluate its Effect on Synovitis Using Ultrasonography in an Egyptian Population Keywords Synovitis
More informationAbatacept (Orencia) for active rheumatoid arthritis. August 2009
Abatacept (Orencia) for active rheumatoid arthritis August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationComparison between ESR and C-Reactive Protein(CRP) as a Marker of Disease activity in Patients with Rheumatoid Arthritis
Original Article Comparison between ESR and C-Reactive Protein(CRP) as a Marker of Disease activity in Patients with Rheumatoid Arthritis Ali M.E. Yousef 1, Fatemah A. Elshabacy 2, Sherry K. Abdelrahman
More informationCHAPTER 4. S. Hirata 1, 2 L. Dirven 1 Y. Shen 3 M. Centola 4 G. Cavet 3 W.F. Lems 5 Y. Tanaka 2 T.W.J. Huizinga 1 C.F. Allaart 1
CHAPTER 4. A multi-biomarker based disease activity (MBDA) score system compared to a conventional disease activity score (DAS) system in the BeSt rheumatoid arthritis (RA) study S. Hirata 1, 2 L. Dirven
More informationDevelopment of Classification and Response Criteria for Rheumatic Diseases
Arthritis & Rheumatism (Arthritis Care & Research) Vol. 55, No. 3, June 15, 2006, pp 348 352 DOI 10.1002/art.22003 2006, American College of Rheumatology EDITORIAL Development of Classification and Response
More informationA 3-page standard protocol to evaluate rheumatoid arthritis (SPERA): Efficient capture of essential data for clinical trials and observational studies
A 3-page standard protocol to evaluate rheumatoid arthritis (SPERA): Efficient capture of essential data for clinical trials and observational studies T. Pincus Division of Rheumatology and Immunology,
More informationFibromyalgia in patients with rheumatoid arthritis. A 10-year follow-up study, results from the Oslo Rheumatoid Arthritis Register
Fibromyalgia in atients with rheumatoid arthritis. A 10-year follow-u study, results from the Oslo Rheumatoid Arthritis Register S.A. Provan, C. Austad, V. Halsaa, H.B. Hammer, T.K. Kvien, T. Uhlig Deartment
More informationIncorporating patient reported outcome measures in clinical practice: development and validation of a questionnaire for inflammatory arthritis
Incorporating patient reported outcome measures in clinical practice: development and validation of a questionnaire for inflammatory arthritis Y. El Miedany 1,2, M. El Gaafary 3, S.S. Youssef 2, D. Palmer
More informationGolimumab: a novel anti-tumor necrosis factor
Golimumab: a novel anti-tumor necrosis factor Rossini M, De Vita S, Ferri C, et al. Biol Ther. 2013. This slide deck represents the opinions of the authors, and not necessarily the opinions of the publisher
More informationORIGINAL ARTICLE. Abstract. Introduction
ORIGINAL ARTICLE Mizoribine Synchronized Methotrexate Therapy should be Considered when Treating Rheumatoid Arthritis Patients with an Inadequate Response to Various Combination Therapies Keigo Ikeda 1,2,
More informationNEW EFFECTIVE TREATMENTS FOR PSORIATIC ARTHRITIS PATIENTS Promising data to support two new drug classes
Annual European Congress of Rheumatology (EULAR) 2017 Madrid, Spain, 14-17 June 2017 NEW EFFECTIVE TREATMENTS FOR PSORIATIC ARTHRITIS PATIENTS Promising data to support two new drug classes Madrid, Spain,
More informationReview. Structural progression in rheumatoid arthritis remission: can MRI predict it? Frederique Gandjbakhch*1 & Violaine Foltz1
Structural in rheumatoid arthritis remission: can MRI predict it? Remission has become an achievable goal in rheumatoid arthritis (RA) thanks to a large choice of drug therapies and improvement of treatment
More informationRheumatology function tests: Quantitative physical measures to monitor morbidity and predict mortality in patients with rheumatic diseases
Rheumatology function tests: Quantitative physical measures to monitor morbidity and predict mortality in patients with rheumatic diseases T. Pincus Division of Rheumatology and Immunology, Department
More informationDAS28 score vs. ultrasound examination for assessment of rheumatoid arthritis disease activity: comparison and discussion of pros and cons
Review paper Reumatologia 215; 53, 4: 213 218 DOI: 1.5114/reum.215.53999 DAS28 score vs. ultrasound examination for assessment of rheumatoid arthritis disease activity: comparison and discussion of pros
More informationPreventing Pain in RA
Preventing Pain in RA Gail S. Kerr, MD, FRCP(Edin) Chief Rheumatology VAMC and Howard University Hospital Professor of Medicine Georgetown and Howard University Hospitals, Washington, DC Clinical Professor
More informationIntroduction ORIGINAL ARTICLE
Mod Rheumatol (2007) 17:28 32 Japan College of Rheumatology 2007 DOI 10.1007/s10165-006-0532-0 ORIGINAL ARTICLE Hisashi Yamanaka Yoshiya Tanaka Naoya Sekiguchi Eisuke Inoue Kazuyoshi Saito Hideto Kameda
More informationHealth Related Quality of Life before, during and after pregnancy in Norwegian women with Rheumatoid Arthritis and Juvenile Idiopathic Arthritis.
Health Related Quality of Life before, during and after pregnancy in Norwegian women with Rheumatoid Arthritis and Juvenile Idiopathic Arthritis. Bente Jakobsen Master Thesis in Clincical Health Science
More informationInvestor Presentation Post-Interim Results Update. September 2011
Investor Presentation Post-Interim Results Update September 2011 Disclaimer This presentation contains general information about the company s activities current as at 2 September 2011. It is provided
More informationThe METEOR initiative: the way forward for optimal, worldwide data integration to improve care for RA patients
The METEOR initiative: the way forward for optimal, worldwide data integration to improve care for RA patients R. van den Berg 1, D. van der Heijde 1, R. Landewé 2,3, K. van Lambalgen 4, T. Huizinga 1,
More informationGuideline on clinical investigation of medicinal products for the treatment of rheumatoid arthritis
14 December 2017 CPMP/EWP/556/95 Rev. 2 Committee for Medicinal Products for Human Use (CHMP) Guideline on clinical investigation of medicinal products for the treatment of Draft Agreed by Rheumatology-Immunology
More informationFaith Matcham, Sam Norton, David L Scott, Sophia Steer, Matthew Hotopf FA I T H M AT C H A M P H D S T U D E N T,
The impact of baseline and persistent symptoms of depression and anxiety on long-term physical health outcomes and response to treatment in Rheumatoid Arthritis Faith Matcham, Sam Norton, David L Scott,
More informationSafety and effectiveness of biologic Disease-Modifying Antirheumatic Drugs in elderly patients with rheumatoid arthritis
1. Title: Safety and effectiveness of biologic Disease-Modifying Antirheumatic Drugs in elderly patients with rheumatoid arthritis 2. Background: The population of older individuals with rheumatoid arthritis
More informationWare NIH Lecture Handouts
Health-Related Quality of Life - 11 John E. Ware, Jr., PhD, Professor and Chief Measurement Sciences Division, Department of Quantitative Health Sciences University of Massachusetts Medical School, Worcester,
More informationBest Practices in Managing Patients with Rheumatoid Arthritis. Kelsey-Seybold Clinic. Implementing Evidenced- Based Medicine in the Management of RA
Best Practices in Managing Patients with Rheumatoid Arthritis Implementing Evidenced- Based Medicine in the Management of RA Organizational Profile (KSC) began in 1949 by founder Dr. Mavis P. Kelsey. Modeling
More informationTitle: The ideal target for psoriatic arthritis? Comparison of remission and low
Title: The ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real life cohort. Leonieke J.J. van Mens, MD 1, Marleen G.H. van de Sande, MD 1, PhD 1, Arno
More informationBest Practices in Managing Patients with Rheumatoid Arthritis. University of Rochester. Adding Patient Reported Outcome Measures
Best Practices in Managing Patients with Rheumatoid Arthritis Adding Patient Reported Outcome Measures Organizational Profile Strong Memorial Hospital is a large tertiary care center located in Rochester,
More informationTocilizumab F. Hoffmann-La Roche Ltd. Protocol MA 27950, Version 3.0 1
Protocol MA 27950, Version 3.0 1 Protocol MA 27950, Version 3.0 2 TABLE OF CONTENTS PROTOCOL ACCEPTANCE FORM... 8 PROTOCOL SYNOPSIS... 9 1. BACKGROUND... 15 1.1 Background on Rheumatoid Arthritis... 15
More information(For National Authority Use Only) Page:
2.0 Synopsis AbbVie Individual Study Table Referring to Part of Dossier: Name of Study Drug: Volume: HUMIRA 40 mg/0.8 ml for subcutaneous injection Page: (For National Authority Use Only) Name of Active
More informationImplementing Outcomes Goals in the Treatment of Rheumatoid Arthritis. Treating Rheumatoid Arthritis To Target
Implementing Outcomes Goals in the Treatment of Rheumatoid Arthritis Treating Rheumatoid Arthritis To Target Max Hamburger, MD May 3, 2012 Sandestin Hilton Sandestin, FL Disease Course of RA RA is a chronic
More informationStudy synopsis of the global non-interventional study SWITCH-RA
Study synopsis of the global non-interventional study SWITCH-RA Protocol number: MA22401 Title of Study: A global multi-centre observational study in RA patients who are non-responders or intolerant to
More informationTreatment of Rheumatoid Arthritis: The Past, the Present and the Future
Treatment of Rheumatoid Arthritis: The Past, the Present and the Future Lai-Ling Winchow FCP(SA) Cert Rheum(SA) Chris Hani Baragwanath Academic Hospital University of the Witwatersrand Outline of presentation
More informationPragmatic and Scientific Advantages of MDHAQ/ RAPID3 Completion by All Patients at All Visits in Routine Clinical Care
S30 Pragmatic and Scientific Advantages of MDHAQ/ RAPID3 Completion by All Patients at All Visits in Routine Clinical Care Theodore Pincus, M.D., Yusuf Yazici, M.D., and Isabel Castrejón, M.D. Abstract
More informationIndividual Study Table Referring to Part of Dossier: Use Only) Name of Study Drug:
2.0 Synopsis AbbVie Inc. Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Adalimumab (Humira ) Page: Name of Active Ingredient: Adalimumab
More informationDiscussion Areas. Patient Reported Outcome Measures in Clinical Practice and Research Arthritis as an Exemplar
Patient Reported Outcome s in Clinical Practice and Research Arthritis as an Exemplar Leigh F. Callahan, PhD Program on Health Outcomes Seminar March 4, 25 Traditionally, clinical measures of biologic
More informationTHE RELIABILITY AND CONSTRUCT VALIDITY OF THE RAQoL: A RHEUMATOID ARTHRITIS-SPECIFIC QUALITY OF LIFE INSTRUMENT
British Journal of Rheumatology 1997;36:878 883 THE RELIABILITY AND CONSTRUCT VALIDITY OF THE RAQoL: A RHEUMATOID ARTHRITIS-SPECIFIC QUALITY OF LIFE INSTRUMENT Z. DE JONG, D. VAN DER HEIJDE, S. P. MCKENNA*
More informationCriteria Inclusion criteria Exclusion criteria. despite treatment with csdmards, NSAIDs, and/or previous anti-tnf therapy and/or
Supplementary Material Table S1 Eligibility criteria (PICOS) for the SLR Criteria Inclusion criteria Exclusion criteria Population Adults (aged 18 years) with active PsA despite treatment with csdmards,
More informationBest Practices in Managing Patients with Rheumatoid Arthritis. Summit Medical Group. Standardizing Protocols and Educating Providers
Best Practices in Managing Patients with Rheumatoid Arthritis Summit Medical Group Standardizing Protocols and Educating Providers Organizational Profile Summit Medical Group, established in 1929, is the
More information1.0 Abstract. Title. Keywords. Adalimumab, Rheumatoid Arthritis, Effectiveness, Safety. Rationale and Background
1.0 Abstract Title Assessment of the safety of adalimumab in rheumatoid arthritis (RA) patients showing rapid progression of structural damage of the joints, who have no prior history of treatment with
More informationThe International Classification of Functioning, Disability and Health (ICF) Core Sets for rheumatoid arthritis: a way to specify functioning
ii40 REPORT The International Classification of Functioning, Disability and Health (ICF) Core Sets for rheumatoid arthritis: a way to specify functioning G Stucki, A Cieza... Today, patients functioning
More informationBiotechnologically produced drugs as second-line therapy for rheumatoid arthritis 1
IQWiG Reports Commission No. A10-01 Biotechnologically produced drugs as second-line therapy for rheumatoid arthritis 1 Executive Summary 1 Translation of the executive summary of the final report Biotechnologisch
More informationTREAT-TO-TARGET IN RHEUMATOID ARTHRITIS
TREAT-TO-TARGET IN RHEUMATOID ARTHRITIS To receive up to 10 CME credits for this activity, complete the evaluation, attestation and post-test answer sheet (minimum passing grade of 70%) and return all
More informationDescription of Study Protocol. Data Collection Summary
AND Evidence Analysis Worksheet Citation Kostoglou-athanassiou I, AthanassiouP, Lyraki A, Raftakis I, Antoniadis C. Vitamin D and rheumatoid arthritis. Ther Adv Endocrinol Metab. 2012; 3(6):181-7. Study
More informationFatigue in rheumatoid arthritis reflects pain, not disease activity
Rheumatology 2006;45:885 889 Advance Access publication 31 January 2006 doi:10.1093/rheumatology/kel021 Concise Report Fatigue in rheumatoid arthritis reflects pain, not disease activity L. C. Pollard,
More informationADaM Considerations and Content in the TA User Guides. Susan J Kenny, PhD Maximum Likelihood, Inc.
ADaM Considerations and Content in the TA User Guides Susan J Kenny, PhD Maximum Likelihood, Inc. Topics to Discuss Focus of ADaM content Overview of TAUGs with ADaM content Specific ADaM content in selected
More informationThe response to the Committee request for additional analyses in section 1.4, MSD follows:
MSD Hertford Road Hoddesdon, Hertfordshire EN11 9BU, UK Telephone +44 (0)1992 452644 Facsimile +44 (0)1992 468175 1 Kate Moore Technology Appraisals Project Manager National Institute for Health and Clinical
More information2.0 Synopsis. Adalimumab DE019 OLE (5-year) Clinical Study Report Amendment 1 R&D/06/095. (For National Authority Use Only)
2.0 Synopsis Abbott Laboratories Name of Study Drug: Humira Name of Active Ingredient: Adalimumab Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Title
More informationPRODUCT INFORMATION HUMIRA
NAME OF THE MEDICINE Adalimumab (rch) DESCRIPTION PRODUCT INFORMATION HUMIRA (adalimumab) is a recombinant human immunoglobulin (IgG1) monoclonal antibody containing only human peptide sequences. was created
More informationThe Patient Global Assessment of Disease Activity in Rheumatoid Arthritis: Identification of Underlying Latent Factors
Rheumatol Ther (2017) 4:201 208 DOI 10.1007/s40744-017-0063-5 BRIEF REPORT The Patient Global Assessment of Disease Activity in Rheumatoid Arthritis: Identification of Underlying Latent Factors Divya N.
More information10/30/2013. Disclosures. Defining Flares in RA RA Flare Group
Disclosures Using PROMIS Instruments to Identify Disease Flares in People with Rheumatoid Arthritis S Bartlett is the Canadian delegate for PROMIS International Recipient of CIHR planning award for Canada
More informationABSTRACT INTRODUCTION. Joseph Markenson, MD, 1 Kathryn Charalambous, PhD, 2 Christopher Viereck, PhD, CCMEP, 3 Derek Dietze, MA, FACEHP, CCMEP 3
US Rheumatologists Attitudes, Practice Habits, Barriers, and Knowledge Gaps in Assessing and Monitoring Patients with Rheumatoid Arthritis according to Recent Recommendations Joseph Markenson, MD, 1 Kathryn
More informationThis essay presents a rationale for any rheumatologist
254 Can RAPID3, an Index Without Formal Joint Counts or Laboratory Tests, Serve to Guide Rheumatologists in Tight Control of Rheumatoid Arthritis in Usual Clinical Care? Theodore Pincus, M.D. Abstract
More informationThe Future of Measuring Patient-Reported Outcomes in Rheumatology
Arthritis Care & Research Vol. 63, No. S11, November 2011, pp S486 S490 DOI 10.1002/acr.20581 2011, American College of Rheumatology COMMENTARY The Future of Measuring Patient-Reported Outcomes in Rheumatology
More informationObesity, weight change and disease activity measures in patients with rheumatoid arthritis
Boston University OpenBU Theses & Dissertations http://open.bu.edu Boston University Theses & Dissertations 2016 Obesity, weight change and disease activity measures in patients with rheumatoid arthritis
More informationPain, sleep and emotional well-being explain the lack of agreement between physician- and patient-perceived remission in early rheumatoid arthritis
Turk et al. BMC Rheumatology (2018) 2:16 https://doi.org/10.1186/s41927-018-0024-9 BMC Rheumatology RESEARCH ARTICLE Open Access Pain, sleep and emotional well-being explain the lack of agreement between
More informationA SURVEY AMONG PATIENTS AND PHYSICIANS EU THE NETHERLANDS
A SURVEY AMONG PATIENTS AND PHYSICIANS EU THE NETHERLANDS COMPARING PHYSICIAN AND PATIENT PERSPECTIVES ON COMMUNICATION ABOUT AND MANAGEMENT OF RHEUMATOID ARTHRITIS (RA) GfK December 2016 415427 & 441858
More informationChinese registry of rheumatoid arthritis (CREDIT): I. Introduction and prevalence of remission in Chinese patients with rheumatoid arthritis
Chinese registry of rheumatoid arthritis (CREDIT): I. Introduction and prevalence of remission in Chinese patients with rheumatoid arthritis C. Yu 1, M. Li 1, X. Duan 2, Y. Fang 3, Q. Li 4, R. Wu 5, S.
More informationSimilar clinical outcomes in rheumatoid arthritis with more versus
Similar clinical outcomes in rheumatoid arthritis with more versus less expensive treatment strategies. Observational data from two rheumatology clinics T. Sokka 1, G. Haugeberg 2,3, J. Asikainen 1, I.J.
More informationClustering Rasch Results: A Novel Method for Developing Rheumatoid Arthritis States for Use in Valuation Studiesvhe_
Volume 13 Number 6 2010 VALUE IN HEALTH Clustering Rasch Results: A Novel Method for Developing Rheumatoid Arthritis States for Use in Valuation Studiesvhe_757 787..795 Helen M. McTaggart-Cowan, PhD, John
More informationPerspective. Combination therapy in rheumatoid arthritis: always the best option? Yasmin Bata1 & Yusuf Yazici*1
Combination therapy in rheumatoid arthritis: always the best option? One of the major developments in the treatment of rheumatoid arthritis over the last decade and a half has been the realization that
More information